Compounds > resiquimod
Page last updated: 2024-09-04

resiquimod and Experimental Mammary Neoplasms

resiquimod has been researched along with Experimental Mammary Neoplasms in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Im, SA; Lee, CK; Lee, M; Lee, YR; Park, CS; Song, S1
He, S; Wang, Y; Yin, T1

Other Studies

2 other study(ies) available for resiquimod and Experimental Mammary Neoplasms

ArticleYear
Resiquimod, a TLR7/8 agonist, promotes differentiation of myeloid-derived suppressor cells into macrophages and dendritic cells.
    Archives of pharmacal research, 2014, Volume: 37, Issue:9

    Topics: Animals; Antigens, Differentiation; Antineoplastic Agents; Carcinoma; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Dendritic Cells; Imidazoles; Immunologic Factors; Macrophages; Male; Mammary Neoplasms, Experimental; Mice, Inbred BALB C; Myeloid Progenitor Cells; Specific Pathogen-Free Organisms; Spleen; Toll-Like Receptor 7; Toll-Like Receptor 8

2014
Toll-like receptor 7/8 agonist, R848, exhibits antitumoral effects in a breast cancer model.
    Molecular medicine reports, 2015, Volume: 12, Issue:3

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Screening Assays, Antitumor; Drug Synergism; Female; Gene Expression; HMGB1 Protein; Imidazoles; Indoles; Mammary Neoplasms, Experimental; Membrane Glycoproteins; Mice, Inbred BALB C; Neoplasm Transplantation; Pyrroles; Sunitinib; Toll-Like Receptor 7; Toll-Like Receptor 8; Up-Regulation

2015